我院中药注射剂实施重点监控管理成效分析
|
摘要
目的比较我院中药注射剂纳入重点监控目录措施前后的临床用药情况,分析中药注射剂重点监控管理取得的成效和不足,为临床安全合理用药及有效管理提供参考。方法通过医院系统调取2015—2017年中药注射剂的使用数据,分析我院中药注射剂进入药品每月使用金额排名前10情况、使用金额、用药频度(DDDs)、药物的利用指数(DUI)、不良反应上报等情况。结果 2016年实施重点监控措施后中药注射剂的使用金额稳步下降,占药品总金额的比例持续降低,DUI值日趋合理,不良反应上报数量不断降低。2016年开始基本实现全部药品使用金额排名前10无中药注射剂的目标。结论我院中药注射剂的监管措施取得了一定成效,但中药注射剂处方点评工作方式和方法有待进一步完善。
Objective To analyze the achievements and shortcomings of the key monitoring measures of traditional Chinese medicine injections(TCMI) in our hospital,by comparing the situation of clinical medication before and after putting TCMI into the key monitoring catalogue,and provide a reference for clinical safe and rational use and effective management. Methods Based on the data collected from the hospital system from 2015 to 2017,the top ten monthly usage amounts,usage amounts,DDDs,DUI and adverse reactions of TCMI in our hospital were analyzed. Results After the implementation of key monitoring measures in 2016,the use amount of TCMI has steadily decreased,the proportion of TCMI in the total amount of drugs has continued to decrease,the DUI value has become more reasonable,and the number of adverse reactions reported has been decreasing. Starting in 2016,we have basically achieved the goal of ranking the top 10 non-TCMI in the total amount of drugs used. Conclusion The regulatory measures of TCMI in our hospital achieve certain results. However,the methods of prescription evaluation of TCMI need to be further improved.
Objective To analyze the achievements and shortcomings of the key monitoring measures of traditional Chinese medicine injections(TCMI) in our hospital,by comparing the situation of clinical medication before and after putting TCMI into the key monitoring catalogue,and provide a reference for clinical safe and rational use and effective management. Methods Based on the data collected from the hospital system from 2015 to 2017,the top ten monthly usage amounts,usage amounts,DDDs,DUI and adverse reactions of TCMI in our hospital were analyzed. Results After the implementation of key monitoring measures in 2016,the use amount of TCMI has steadily decreased,the proportion of TCMI in the total amount of drugs has continued to decrease,the DUI value has become more reasonable,and the number of adverse reactions reported has been decreasing. Starting in 2016,we have basically achieved the goal of ranking the top 10 non-TCMI in the total amount of drugs used. Conclusion The regulatory measures of TCMI in our hospital achieve certain results. However,the methods of prescription evaluation of TCMI need to be further improved.
引文
[1] 国家药典委员会.中华人民共和国药典临床用药须知(中药成方制剂卷) [M].北京:中国医药科技出版社,2015:18.
[2] 赵爱梅.中药注射剂不良反应逐年上升的原因分析[J] .世界最新医学信息文摘,2016,16(10):119-121.
[3] 杨洪军,于振兰.中药注射剂安全性问题文献研究[J] .中国药房,2017,28(11):1489-1492.
[4] 胡国仕,胡艳芬,徐文云,等.2013—2016年昭通市第一人民医院中药注射剂应用分析[J].中国医院用药评价与分析,2017,17(3):403-409.
[5] 杨静,杨阿罗. 2012—2016年我院中药注射剂用药情况分析[J].山西医科大学学报,2017,48(9):960-962.
[6] 闫峻峰,刘翌.四川省医疗机构辅助用药的药事管理实践[J].中国药房,2017,28(4):450-454.
[7] 杨峰,潘春晓,张小丹,等.安徽省肿瘤医院抗肿瘤辅助用药应用合理性分析[J].中国医院用药评价与分析,2016,16(8):1126-1128.
[8] 贾萍,袁何梦婕,王华飞,等.我院重点监控药品使用情况调查及分析[J].医学信息,2016,29(26):88-90.
[9] 路丹,卢成华.我院2013—2015年辅助用药应用分析[J].中国药房,2017,28(8):1030-1033.
[10] 李海燕,胡斌.西安地区11家三级医院2013-2015年辅助用药使用分析[J].中国药房,2016,27(23):3188-3190.
[2] 赵爱梅.中药注射剂不良反应逐年上升的原因分析[J] .世界最新医学信息文摘,2016,16(10):119-121.
[3] 杨洪军,于振兰.中药注射剂安全性问题文献研究[J] .中国药房,2017,28(11):1489-1492.
[4] 胡国仕,胡艳芬,徐文云,等.2013—2016年昭通市第一人民医院中药注射剂应用分析[J].中国医院用药评价与分析,2017,17(3):403-409.
[5] 杨静,杨阿罗. 2012—2016年我院中药注射剂用药情况分析[J].山西医科大学学报,2017,48(9):960-962.
[6] 闫峻峰,刘翌.四川省医疗机构辅助用药的药事管理实践[J].中国药房,2017,28(4):450-454.
[7] 杨峰,潘春晓,张小丹,等.安徽省肿瘤医院抗肿瘤辅助用药应用合理性分析[J].中国医院用药评价与分析,2016,16(8):1126-1128.
[8] 贾萍,袁何梦婕,王华飞,等.我院重点监控药品使用情况调查及分析[J].医学信息,2016,29(26):88-90.
[9] 路丹,卢成华.我院2013—2015年辅助用药应用分析[J].中国药房,2017,28(8):1030-1033.
[10] 李海燕,胡斌.西安地区11家三级医院2013-2015年辅助用药使用分析[J].中国药房,2016,27(23):3188-3190.